Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk A/S NVO has declared that its GLP ... Lilly’s Next-Generation Triple Agonist GLP-1 Drug Looks Very Promising Lilly has also been working on their next-generation GLP-1 drug ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Novo Nordisk has tumbled on GLP-1 agonist ... Research from Grand View Research estimates GLP-1 agonist sales in North America could triple from $41 billion last year to $126 billion in 2030 ...

The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to a long-acting amylin ...

Research from Grand View Research estimates GLP-1 agonist sales in North America could triple from $41 billion last year to $126 billion in 2030, averaging 18% annualized growth over the next five ...

Developed by Novo Nordisk, Monlunabant is not a GLP-1 receptor agonist at all, but a treatment for obesity. Instead, it focuses around the cannabinoid CB1 receptor. “Monlunabant is an investigational ...